Peptide·plain sequence-like

ATLPC0028313

SDKP

Routes

Compare in workbench Download release API JSON

Length
4 aa
Monoisotopic mass
445.2 Da
Net charge @ pH 7.4
0.00
Isoelectric point
6.34
GRAVY
-2.450

Coveragecounts only · not riskATLPC0028313

Measurements
20
Endpoints
2
Domains
2/5
Products
—

13 stability measurements
7 clearance measurements
No immunogenicity context
1 liability motif

Jump to domain

Open the matching evidence section below

All evidence index · 20

Exposure / Absorption

No evidence

Distribution / Barrier

No evidence

Metabolic & Proteolytic Stability

13 measurements

Excretion / Persistence

7 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 4
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0030774	—	—	—	Notation only	2

Residue view

Residue display

4 residues

S1D2K3P4

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

SDKP

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors4 aa · pI 6.3 · GRAVY -2.45

Length: 4 aa
Monoisotopic mass: 445.22 Da
Average mass: 445.47 Da
Net charge at pH 7.4: 0.00
Estimated pI: 6.34
GRAVY: -2.450
KD-positive residues: 0.0%
Aromatic residues: 0.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.69
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

1.96

pH 5

0.11

pH 6

0.01

pH 7.4

-0.06

pH 9

-0.73

pH 12

-1.94

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 25.0%

Basic (K,R,H)

1 · 25.0%

Polar uncharged (N,Q,S,T)

1 · 25.0%

Conformational / sulfur (G,P,C)

1 · 25.0%

Top residues

D125.0%K125.0%P125.0%S125.0%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

1-4

SDKP

GRAVY -2.450

Most hydrophilic window

1-4

SDKP

GRAVY -2.450

1 local hydropathy window scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Pro/Gly-rich sequence

P/G · pos 4

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

0.00

Instability index

-32.6

At or below 40 — predicted stable in vitro.

Boman index

4.42 kcal/mol

Above 2.48 — elevated potential protein-binding.

Molar extinction coefficient (280 nm)

0 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.00

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Metabolic & Proteolytic Stability

13 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability13 records · 13 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	3.5 hours 12600 seconds	Eligible when experimental context matches	HPLC · Fetal calf serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Fetal calf serum · in vitro · Source: Primary reference linked	Reference
2	18 hours 64800 seconds	Eligible when experimental context matches	HPLC · Fetal calf serum + 1μM catropril	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Fetal calf serum · in vitro · Source: Primary reference linked	Reference
3	1.75 hours 6300 seconds	Eligible when experimental context matches	HPLC · Heat inactivated calf serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Heat inactivated calf serum · in vitro · Source: Primary reference linked	Reference
4	11.5 hours 41400 seconds	Eligible when experimental context matches	HPLC · Heat inactivated calf serum + 1μM catropril	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Heat inactivated calf serum · in vitro · Source: Primary reference linked	Reference
5	5.5 hours 19800 seconds	Eligible when experimental context matches	HPLC · Horse serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Horse serum · in vitro · Source: Primary reference linked	Reference
6	0.5 hours 1800 seconds	Eligible when experimental context matches	HPLC · Horse serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Horse serum · in vitro · Source: Primary reference linked	Reference
7	1.3 hours 4680 seconds	Eligible when experimental context matches	HPLC · human · Human plasma	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Human plasma · in vitro · Source: Primary reference linked	Reference
8	161.5 ± 5.79 Minutes 9690 seconds	Eligible when experimental context matches	HPLC · human · human serum	Result: Reported point value · Molecular form: ATLPF0030774 · Dose/window: 100 μM · Human Serum Protease · In Vitro · Source: Primary reference linked	Reference
9	6.47 ± 1.53 Minutes 388.2 seconds	Eligible when experimental context matches	HPLC · human · human serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 100 μM · Human Serum Protease · In Vitro · Source: Primary reference linked	Reference
10	0.75 hours 2700 seconds	Eligible when experimental context matches	HPLC · human · Human serum	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Human serum · in vitro · Source: Primary reference linked	Reference

1–10 / 13

Excretion / Persistence

7 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life7 records · 5 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	1.7 hours 6120 seconds	Eligible when experimental context matches	HPLC · human · Human blood	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Human blood · in vitro · Source: Primary reference linked	Reference
2	10 minutes 600 seconds	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 10-4M conc · Rabbit lung angiotensin I converting enzyme · in vitro · Source: Primary reference linked	Reference
3	25 minutes 1500 seconds	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 10-7M conc. · Rabbit lung angiotensin I converting enzyme · in vitro · Source: Primary reference linked	Reference
4	50 minutes 3000 seconds	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 10nM conc. · in vitro · Source: Primary reference linked	Reference
5	80 minutes 4800 seconds	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 1mM · in vitro · Source: Primary reference linked	Reference
6	systemic pk half life unspecified phase: 176.5 ± 6.45 Minutes 10590 seconds	Use only explicitly reported fields	RP-HPLC · rat · Rats serum	Result: Reported point value · Molecular form: ATLPF0030774 · Route: IV · Rats serum protease · In Vivo · Source: Primary reference linked	Reference
7	systemic pk half life unspecified phase: 9.65 ± 1.78 Minutes 579 seconds	Use only explicitly reported fields	RP-HPLC · rat · Rats serum	Result: Reported point value · Molecular form: ATLPF0041122 · Route: IV · Rats serum protease · In Vivo · Source: Primary reference linked	Reference

Evidence landscape

20 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

0 evidence records

Metabolic & Proteolytic Stability

13 evidence records

Excretion / Persistence

7 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Serum Plasma Stability

Half Life

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	6 hours 21,600 seconds	Reported point value	Eligible when experimental context matches	HPLC · mouse · Mouse serum + 1μM catropril	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Mouse serum · in vitro	Reference Primary reference linked
2	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	3.5 hours 12,600 seconds	Reported point value	Eligible when experimental context matches	HPLC · Fetal calf serum	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Fetal calf serum · in vitro	Reference Primary reference linked
3	Excretion / Persistence Persistence	Half Life	80 minutes 4,800 seconds	Reported point value	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Dose/window: 1mM · in vitro	Reference Primary reference linked
4	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	6.47 ± 1.53 Minutes 388.2 seconds	Reported point value	Eligible when experimental context matches	HPLC · human · human serum	Dose/window: 100 μM · Protease: Human Serum Protease · In Vitro	Reference Primary reference linked
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	5.5 hours 19,800 seconds	Reported point value	Eligible when experimental context matches	HPLC · Horse serum	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Horse serum · in vitro	Reference Primary reference linked
6	Excretion / Persistence Persistence	Half Life	9.65 ± 1.78 Minutes 579 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Use only explicitly reported fields	RP-HPLC · rat · Rats serum	Route: IV · Protease: Rats serum protease · In Vivo	Reference Primary reference linked
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.75 hours 2,700 seconds	Reported point value	Eligible when experimental context matches	HPLC · human · Human serum	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Human serum · in vitro	Reference Primary reference linked
8	Excretion / Persistence Persistence	Half Life	25 minutes 1,500 seconds	Reported point value	Eligible when experimental context matches	Radioactivity measured with liquid-scintillation counter · human · Human venous blood sample	Dose/window: 10-7M conc. · Protease: Rabbit lung angiotensin I converting enzyme · in vitro	Reference Primary reference linked
9	Excretion / Persistence Persistence	Half Life	1.7 hours 6,120 seconds	Reported point value	Eligible when experimental context matches	HPLC · human · Human blood	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Human blood · in vitro	Reference Primary reference linked
10	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	4 hours 14,400 seconds	Reported point value	Eligible when experimental context matches	HPLC · mouse · Mouse serum	Dose/window: 4 X lO-7M, 10 μCi · Protease: Proteases from Mouse serum · in vitro	Reference Primary reference linked

1–10 / 20

Identity & reference map

20 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary3 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 3
Measurements: 20
ATL peptide ID: ATLPC0028313

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 20

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 20

Different notation

Reported notation does not resolve to the current display sequence.

0 / 20

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

20 / 20

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

SDKP

Reported names

No distinct human-readable aliases are exposed.

Reference map3 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	PersistenceStability Half Life, Serum Plasma Stability	No reported alias	12 identity 12 evidence
Reference Open	PersistenceStability Half Life, Serum Plasma Stability	No reported alias	4 identity 4 evidence
Reference Open	Persistence Half Life	No reported alias	4 identity 4 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0028313
Identity type: canonical sequence
ADMET endpoints: 2
Evidence records: 20
Reference groups: 3
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0028313

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0028313' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0030774

—

Notation only

Value

Analysis use

Assay / model

Result context

Reference

3.5 hours

12600 seconds

Eligible when experimental context matches

HPLC · Fetal calf serum

Result: Reported point value · Molecular form: ATLPF0041122 · Dose/window: 4 X lO-7M, 10 μCi · Proteases from Fetal calf serum · in vitro · Source: Primary reference linked